Calamos Advisors LLC Has $1.33 Million Stake in Artivion, Inc. (NYSE:AORT)

Calamos Advisors LLC trimmed its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 14.3% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 54,000 shares of the company's stock after selling 9,029 shares during the quarter. Calamos Advisors LLC owned approximately 0.13% of Artivion worth $1,327,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Legacy Advisors LLC acquired a new position in shares of Artivion during the first quarter valued at $28,000. Smartleaf Asset Management LLC increased its holdings in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after purchasing an additional 786 shares during the period. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Artivion during the fourth quarter valued at $64,000. KLP Kapitalforvaltning AS acquired a new position in shares of Artivion during the fourth quarter valued at $194,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Artivion during the fourth quarter valued at $275,000. 86.37% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Artivion news, SVP Marshall S. Stanton sold 15,000 shares of the firm's stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $29.50, for a total transaction of $442,500.00. Following the completion of the sale, the senior vice president directly owned 64,200 shares in the company, valued at approximately $1,893,900. This trade represents a 18.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Jean F. Holloway sold 8,748 shares of the firm's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $29.00, for a total value of $253,692.00. Following the sale, the senior vice president owned 178,510 shares of the company's stock, valued at $5,176,790. The trade was a 4.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,954 shares of company stock worth $2,108,525. 7.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AORT has been the topic of a number of research analyst reports. JMP Securities reissued a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Finally, Canaccord Genuity Group started coverage on Artivion in a report on Tuesday, June 17th. They set a "buy" rating and a $35.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $32.40.

Artivion Trading Up 1.2%

Shares of NYSE:AORT traded up $0.40 during midday trading on Thursday, reaching $32.55. The company had a trading volume of 569,976 shares, compared to its average volume of 339,602. The company has a debt-to-equity ratio of 1.08, a quick ratio of 3.95 and a current ratio of 5.53. Artivion, Inc. has a 1-year low of $21.97 and a 1-year high of $32.92. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -65.10 and a beta of 1.62. The company has a fifty day simple moving average of $29.16 and a two-hundred day simple moving average of $27.64.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. The company had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Research analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.